Volcano: Learning To Thrive In A Declining PCI Market
Executive Summary
Long used to a growing market driven by favorable demographics, cardiovascular companies are facing a declining PCI market, in the US and Europe at least, and are forced to shift their strategies to adapt. Volcano, for one, is articulating a new way to approach this declining market.
You may also be interested in...
Doc Payments For Coronary Stenting Will Drop Next Year, But Will Better Reflect Procedure Complexity
New coding structure for coronary stenting recognizes more complex procedure with higher levels of Medicare reimbursement, but overall physician payments for percutaneous coronary interventions will go down in 2013.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.